Immuneering Appoints Igor Matushansky As CMO

(RTTNews) - Immuneering Corp. (IMRX), a clinical-stage oncology company, Thursday announced that Igor Matushansky has joined the firm as Chief Medical Officer.

The appointment comes as Immuneering is planning to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in the second quarter. Matushansky will oversee clinical activities, guiding medical and operational aspects of the company's development programs.

It includes leading a Phase 2a study of IMM-1-104 for pancreatic cancer, lung cancer, and melanoma, as well as plans to initiate a pivotal Phase 3 clinical trial in pancreatic cancer.

Matushansky was previously Chief Medical Officer at Sail Biomedicines. Prior to that, he had served in various roles at Ipsen Pharmaceuticals, Daiichi Sankyo and Novartis.

Wednesday, Immuneering had closed trading at $1.68 on the Nasdaq.